Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 19, 2020 09:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Update on Omburtamab in DIPG

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
November 05, 2020 16:01 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Third Quarter 2020 Financial Results and Recent Corporate Developments

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a development-stage clinical biopharmaceutical company focused on the development and...
October 29, 2020 09:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs to Announce Third Quarter 2020 Financial and Operating Results on November 5, 2020

NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended...
October 26, 2020 09:10 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces FDA Clearance of IND for Lutetium-177 Labeled Omburtamab Antibody for Adult Indications

NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
October 16, 2020 09:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma

NEW YORK, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
October 14, 2020 09:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces FDA Clearance of IND for its Lutetium-177 Labeled Omburtamab Antibody

NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
October 07, 2020 09:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs’ Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA

NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
October 05, 2020 16:01 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and...
August 06, 2020 16:01 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate Developments

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
August 06, 2020 09:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDA

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and...